Shares of other companies:
May 11, 2024 AppLovin Joins Elite 100% Return Club!
Tesla Is Selling More Than Cars With FSD
May 17, 2024
Nvidia Faces Macro Headwinds And Micro Tailwinds
May 15, 2024
Tesla: Challenges Remain Despite Improving Narrative
May 15, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ALLR Stock News and Mentions of Allarity Therapeutics, Inc. Stocktwits
Updated: May 18, 2024 (01:07)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Allarity Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Allarity Therapeutics, Inc. (ALLR).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Allarity Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Allarity Therapeutics, Inc. (ALLR)
May 7, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
All You Need to Know About Allarity Therapeutics, Inc. ( ALLR ) Rating Upgrade to Buy
Allarity Therapeutics, Inc. (ALLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
In Article Trend: Somewhat-Bullish
May 7, 2024 (13:30) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- Conversions Eliminate All Variable Priced Derivative Securities ...
In Article Trend: Neutral
May 6, 2024 (12:00) / "GlobeNewswire" (by Inc.)
Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- Stockholders' equity significantly surpasses the $2.5 million minimum required by ...
In Article Trend: Neutral
May 2, 2024 (16:29) / "Benzinga" (by Vandana Singh)
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday? - Allarity Therapeutics ( NASDAQ:ALLR )
Allarity Therapeutics Inc ALLR shares are trading higher on a strong session volume of 67 million, as per the data from Benzinga Pro. The company announced the early discontinuation of its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer.
In Article Trend: Somewhat-Bullish
May 2, 2024 (12:00) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Boston ( May 2, 2024 ) -Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel ...
In Article Trend: Neutral
April 29, 2024 (11:00) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Boston ( April 29, 2024 ) - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock ...
In Article Trend: Neutral
April 17, 2024 (13:10) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550 ( b ) ( 1 )
Boston ( April 17, 2024 ) -Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance ...
In Article Trend: Neutral
April 15, 2024 (10:04) / "Business Insider" (by Avi Kapoor)
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why Medical Properties Trust Shares Are Trading Higher By Around 13%. Here Are 20 Stocks Moving Premarket - Markets Insider ...
In Article Trend: Neutral
April 15, 2024 (09:45) / "Benzinga" (by Avi Kapoor)
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Medical Properties Trust ( NYSE:MPW )
Shares of Medical Properties Trust, Inc. MPW rose sharply in today's pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. Medical Properties Trust shares jumped 13.1% to $4.51 in pre-market trading. Here are some other stocks moving in pre-market ...
In Article Trend: Neutral
April 12, 2024 (09:32) / "Benzinga" (by Avi Kapoor)
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - NextPlat ( NASDAQ:NXPL )
Shares of NextPlat Corp NXPL rose sharply in today's pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged 29.8% to $1.96 in pre-market trading. Here are some other stocks moving in pre-market trading.
In Article Trend: Neutral
April 11, 2024 (10:14) / "Benzinga" (by Avi Kapoor)
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - Rallybio ( NASDAQ:RLYB )
Shares of Rallybio Corporation RLYB rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rallybio shares jumped rose 77.9% to $2.90 in pre-market trading.
In Article Trend: Neutral
April 8, 2024 (10:05) / "Business Insider" (by Avi Kapoor)
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%. Here Are 20 Stocks Moving Premarket - Markets Insider ...
In Article Trend: Neutral
April 8, 2024 (09:15) / "Benzinga" (by Avi Kapoor)
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Antelope Ent Hldgs ( NASDAQ:AEHL ) , Allarity Therapeutics ( NASDAQ:ALLR )
Shares of Esperion Therapeutics, Inc. ESPR shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations. Esperion Therapeutics shares climbed 7.1% to $3.47 pre-market trading.
In Article Trend: Neutral
April 5, 2024 (09:45) / "Benzinga" (by Avi Kapoor)
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket - Reliance Global Group ( NASDAQ:RELI )
Shares of Reliance Global Group, Inc. RELI fell sharply in today's pre-market trading after reporting financial results for the year ended Dec 31, 2023. Reliance Global Group posted a net loss of $12.0 million for 2023, compared to net income of $6.5 million in 2022..
In Article Trend: Neutral
April 4, 2024 (13:15) / "GlobeNewswire" (by Inc.)
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Boston ( April 4, 2024 ) - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of ...
In Article Trend: Neutral
March 27, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer - Allarity Therapeutics ( NASDAQ:ALLR )
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA® and dovitinib is de-prioritized The Company has been able to reduce costs materially
In Article Trend: Neutral
March 27, 2024 (12:30) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
• The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development • Further development of IXEMPRA® and dovitinib is de-prioritized • The Company has been able to reduce costs materially
In Article Trend: Neutral
March 25, 2024 (11:30) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550 ( a ) ( 2 ) and 5550 ( b ) ( 1 )
Boston ( March 25, 2024 ) - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to ...
In Article Trend: Neutral
Related stocks from Healthcare sector
RenovoRx, Inc. (RNXT)
DENTSPLY SIRONA Inc. (XRAY)
Petros Pharmaceuticals, Inc. (PTPI)
Change Healthcare Inc. (CHNG)
Bright Green Corporation (BGXX)
IDEXX Laboratories, Inc. (IDXX)
Johnson & Johnson (JNJ)
Teva Pharmaceutical Industries Lim. (TEVA) (TEVA)
Kiniksa Pharmaceuticals, Ltd. (KNSA)
Inovio Pharmaceuticals, Inc. (INO)
This website uses cookies to ensure you get the best experience on our website